CA2276013A1 - Utilisation d'inhibiteurs de pro-teasomes dans le traitement du cancer, de l'inflammation, de ma-ladies autoimmunes, du rejet du greffon et du choc septique - Google Patents

Utilisation d'inhibiteurs de pro-teasomes dans le traitement du cancer, de l'inflammation, de ma-ladies autoimmunes, du rejet du greffon et du choc septique Download PDF

Info

Publication number
CA2276013A1
CA2276013A1 CA002276013A CA2276013A CA2276013A1 CA 2276013 A1 CA2276013 A1 CA 2276013A1 CA 002276013 A CA002276013 A CA 002276013A CA 2276013 A CA2276013 A CA 2276013A CA 2276013 A1 CA2276013 A1 CA 2276013A1
Authority
CA
Canada
Prior art keywords
cells
proteasome
lac
activity
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002276013A
Other languages
English (en)
Inventor
Jiangping Wu
Xin Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Montreal
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002219867A external-priority patent/CA2219867A1/fr
Application filed by Individual filed Critical Individual
Priority to CA002276013A priority Critical patent/CA2276013A1/fr
Publication of CA2276013A1 publication Critical patent/CA2276013A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002276013A 1997-10-31 1998-10-29 Utilisation d'inhibiteurs de pro-teasomes dans le traitement du cancer, de l'inflammation, de ma-ladies autoimmunes, du rejet du greffon et du choc septique Abandoned CA2276013A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002276013A CA2276013A1 (fr) 1997-10-31 1998-10-29 Utilisation d'inhibiteurs de pro-teasomes dans le traitement du cancer, de l'inflammation, de ma-ladies autoimmunes, du rejet du greffon et du choc septique

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CA002219867A CA2219867A1 (fr) 1997-10-31 1997-10-31 Utilisation d'inhibiteurs du proteasome dans le traitement du cancer, de l'inflammation, des maladies auto-immunes, du rejet de greffe et du choc septique
CA2,219,867 1997-10-31
CA002276013A CA2276013A1 (fr) 1997-10-31 1998-10-29 Utilisation d'inhibiteurs de pro-teasomes dans le traitement du cancer, de l'inflammation, de ma-ladies autoimmunes, du rejet du greffon et du choc septique
PCT/CA1998/001010 WO1999022729A1 (fr) 1997-10-31 1998-10-29 Utilisation d'inhibiteurs de proteasomes dans le traitement du cancer, de l'inflammation, de maladies autoimmunes, du rejet du greffon et du choc septique

Publications (1)

Publication Number Publication Date
CA2276013A1 true CA2276013A1 (fr) 1999-05-14

Family

ID=31189082

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002276013A Abandoned CA2276013A1 (fr) 1997-10-31 1998-10-29 Utilisation d'inhibiteurs de pro-teasomes dans le traitement du cancer, de l'inflammation, de ma-ladies autoimmunes, du rejet du greffon et du choc septique

Country Status (1)

Country Link
CA (1) CA2276013A1 (fr)

Similar Documents

Publication Publication Date Title
AU770798B2 (en) The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
US20020049157A1 (en) Use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
Marzo et al. Caspases disrupt mitochondrial membrane barrier function
Mandic et al. Calpain-mediated Bid cleavage and calpain-independent Bak modulation: two separate pathways in cisplatin-induced apoptosis
Bardet et al. The T‐cell fingerprint of MALT 1 paracaspase revealed by selective inhibition
Chandra et al. Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes
Quan et al. The development of novel therapies for rheumatoid arthritis
Stangl et al. Long‐term up‐regulation of eNOS and improvement of endothelial function by inhibition of the ubiquitin–proteasome pathway
Barnes New therapies for chronic obstructive pulmonary disease
Wang et al. Role of proteasomes in T cell activation and proliferation
Luo et al. A PROTEASOME INHIBITOR EFFECTIVELY PREVENTS MOUSE HEART ALLOGRAFT REJECTION1
Moon et al. PDE4 inhibitors activate a mitochondrial apoptotic pathway in chronic lymphocytic leukemia cells that is regulated by protein phosphatase 2A
Pendergraft III et al. Proteinase 3 sidesteps caspases and cleaves p21Waf1/Cip1/Sdi1 to induce endothelial cell apoptosis
Klisovic et al. Depsipeptide (FR901228) inhibits proliferation and induces apoptosis in primary and metastatic human uveal melanoma cell lines
US20060293265A1 (en) Methods involving aldose reductase inhibitors
Park et al. Monensin-mediated growth inhibition in NCI-H929 myeloma cells via cell cycle arrest and apoptosis
Schliep et al. Functional evaluation of the role of inhibitor of apoptosis proteins in chronic lymphocytic leukemia
US7786170B2 (en) Histone deacetylase inhibitor enhancement of trail-induced apoptosis
Petit et al. Role of CD95‐activated caspase‐1 processing of IL‐1β in TCR‐mediated proliferation of HIV‐infected CD4+ T cells
Chae et al. Activation of caspase-8 in 3-deazaadenosine-induced apoptosis of U-937 cells occurs downstream of caspase-3 and caspase-9 without Fas receptor-ligand interaction
Bogner et al. Cycling B-CLL cells are highly susceptible to inhibition of the proteasome: involvement of p27, early D-type cyclins, Bax, and caspase-dependent and-independent pathways
US7364719B2 (en) Vasoregulating compounds and methods of their use
CA2276013A1 (fr) Utilisation d'inhibiteurs de pro-teasomes dans le traitement du cancer, de l'inflammation, de ma-ladies autoimmunes, du rejet du greffon et du choc septique
CA2372316A1 (fr) Utilisation d'inhibiteurs de proteasome pour le traitement du cancer, des inflammations, des maladies autoimmunes, des rejets de greffes, et du choc septique
Leach et al. Influence of chloroquine on diet-induced pancreatitis

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20051031